Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety.

Trial Design: Open-label, randomised, controlled, pilot proof-of-concept clinical trial.

Methods: Participants: Antiretroviral naïve adult males with CD4 count ≥350cells/mm.

Interventions: Patients were randomised to receive thalidomide 200mg QD for 3weeks (Thalidomide group) or not (Control group) and followed for 48weeks.

HIV-1 resistance testing influences treatment decision-making.

Objective: To investigates how the use of HIV-1 resistance tests influences physician decision-making.

Methods: Ten experienced reference physicians from the Brazilian Network for Drug Resistance each received ten patients' case histories. The selected patients had experienced at least two virological failures.